Diagnostics' Comeback Despite a lackluster show
Post# of 30065
Posted On: 03/08/2015 11:12:30 PM
Diagnostics' Comeback
Despite a lackluster showing in the M&A arena as of late, the medical diagnostics market is ripe for activity. Since the latter half of 2014, a handful of diagnostics transactions have been announced (even from unlikely suitors), including American Liberty Petroleum Corporation's (OTC: OREO) purchase of Avant Diagnostics.
Roche has kept busy as well, snapping up non-invasive prenatal testing company Ariosa Diagnostics and entering an Asset Purchase Agreement with AvanSci Bio.
Consolidation in the diagnostics sector is bound to grow this year as businesses fight for visibility into new molecules. Within the first month of 2015 alone, there's been a notable uptick in diagnostics deals, including DNA Electronic's $24 million purchase of nanoMR, Amarantus BioScience's acquisition of DioGenix, and Natus Medical's acquisition of Global Neuro-Diagnostics.
http://m.benzinga.com/article/5220037?utm_ref...nBLTeCVKLQ
Despite a lackluster showing in the M&A arena as of late, the medical diagnostics market is ripe for activity. Since the latter half of 2014, a handful of diagnostics transactions have been announced (even from unlikely suitors), including American Liberty Petroleum Corporation's (OTC: OREO) purchase of Avant Diagnostics.
Roche has kept busy as well, snapping up non-invasive prenatal testing company Ariosa Diagnostics and entering an Asset Purchase Agreement with AvanSci Bio.
Consolidation in the diagnostics sector is bound to grow this year as businesses fight for visibility into new molecules. Within the first month of 2015 alone, there's been a notable uptick in diagnostics deals, including DNA Electronic's $24 million purchase of nanoMR, Amarantus BioScience's acquisition of DioGenix, and Natus Medical's acquisition of Global Neuro-Diagnostics.
http://m.benzinga.com/article/5220037?utm_ref...nBLTeCVKLQ
(0)
(0)